Shirvani SM, Jiang J, Chang JY, Gomez, DR, Welsh JW, Swisher SG , Buchholz TA, Smith BD
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
It also gives sensorial benefits to the formula and when used in cleansers, it helps to make them milder and gentler
It should not be used with other GLP-1 medications or Tirzepatide, and other diabetes medicine doses may need adjustment to lower the risk of low blood sugar
